Skip to Main Content

Like the proverbial tortoise, a new analysis finds that while the pharmaceutical industry is taking steps to provide access to its medicines, it is doing so at a slower pace than is needed for lower-income countries.

The most notable sign of progress is in the R&D planning stages, as more drug makers are thinking ahead about access issues. Specifically, eight companies are developing approaches for systematically ensuring all of their R&D projects are positioned to increase access in low-income countries after product launches.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!